Evidence map›Paper›PMID 26964104›Full record

ArticlePloS one2016

Loss of ATP-Sensitive Potassium Channel Surface Expression in Heart Failure Underlies Dysregulation of Action Potential Duration and Myocardial Vulnerability to Injury.

Zhan Gao, Ana Sierra, Zhiyong Zhu, Siva Rama Krishna Koganti, Ekaterina Subbotina, Ankit Maheshwari, Mark E Anderson, Leonid V Zingman, Denice M Hodgson-Zingman

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Research progress on the role of CaMKII in heart disease.American journal of translational research · 2020
    Review
  6. Molecular Bases of Brain Preconditioning.Frontiers in neuroscience · 2017
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Zhan GaoDepartment of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa, United States of America.
Ana SierraDepartment of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa, United States of America.
Zhiyong ZhuDepartment of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa, United States of America.
Siva Rama Krishna KogantiDepartment of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa, United States of America.
Ekaterina SubbotinaDepartment of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa, United States of America.
Ankit MaheshwariDepartment of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa, United States of America.
Mark E AndersonDepartment of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa, United States of America.
Leonid V ZingmanDepartment of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa, United States of America.
Denice M Hodgson-ZingmanDepartment of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa, United States of America.
University of Iowa · USFraternal Order of Eagles · US

Funding

Mitochondrial Calmodulin Kinase II in Physiology and DiseaseR01HL070250 · NHLBI · VANDERBILT UNIVERSITY · PI ANDERSON, MARK E · 2002 to 2017
$5.2M
Methionine sulfoxide reductase A and oxidized CaMKII in structural heart diseaseR01HL079031 · NHLBI · UNIVERSITY OF IOWA · PI ANDERSON, MARK E · 2006 to 2015
$3.3M
CaMKII in Sinus Node Physiology and DiseaseR01HL096652 · NHLBI · UNIVERSITY OF IOWA · PI ANDERSON, MARK E · 2009 to 2016
$3.0M
Oxidized CaMKII in Atrial FibrillationR01HL113001 · NHLBI · UNIVERSITY OF IOWA · PI ANDERSON, MARK E · 2012 to 2016
$1.9M
Control of KATP channel expression by CaMKII: role in heart failure resistanceR01HL113089 · NHLBI · UNIVERSITY OF IOWA · PI HODGSON-ZINGMAN, DENICE · 2012 to 2016
$1.9M
Skeletal muscle KATP channels determine bodily energy balanceR01DK092412 · NIDDK · UNIVERSITY OF IOWA · PI ZINGMAN, LEONID · 2012 to 2016
$1.6M
BLRD VA I01 BX000718NHLBI NIH HHS HL070250NHLBI NIH HHS HL079031NHLBI NIH HHS HL096652NHLBI NIH HHS HL113001NHLBI NIH HHS HL113089NHLBI NIH HHS R01 HL070250NHLBI NIH HHS R01 HL079031NHLBI NIH HHS R01 HL096652NHLBI NIH HHS R01 HL113001NHLBI NIH HHS R01 HL113089NIDDK NIH HHS DK092412NIDDK NIH HHS R01 DK092412
6 · The paper itself

Abstract

The search for new approaches to treatment and prevention of heart failure is a major challenge in medicine. The adenosine triphosphate-sensitive potassium (KATP) channel has been long associated with the ability to preserve myocardial function and viability under stress. High surface expression of membrane KATP channels ensures a rapid energy-sparing reduction in action potential duration (APD) in response to metabolic challenges, while cellular signaling that reduces surface KATP channel expression blunts APD shortening, thus sacrificing energetic efficiency in exchange for greater cellular calcium entry and increased contractile force. In healthy hearts, calcium/calmodulin-dependent protein kinase II (CaMKII) phosphorylates the Kir6.2 KATP channel subunit initiating a cascade responsible for KATP channel endocytosis. Here, activation of CaMKII in a transaortic banding (TAB) model of heart failure is coupled with a 35-40% reduction in surface expression of KATP channels compared to hearts from sham-operated mice. Linkage between KATP channel expression and CaMKII is verified in isolated cardiomyocytes in which activation of CaMKII results in downregulation of KATP channel current. Accordingly, shortening of monophasic APD is slowed in response to hypoxia or heart rate acceleration in failing compared to non-failing hearts, a phenomenon previously shown to result in significant increases in oxygen consumption. Even in the absence of coronary artery disease, failing myocardium can be further injured by ischemia due to a mismatch between metabolic supply and demand. Ischemia-reperfusion injury, following ischemic preconditioning, is diminished in hearts with CaMKII inhibition compared to wild-type hearts and this advantage is largely eliminated when myocardial KATP channel expression is absent, supporting that the myocardial protective benefit of CaMKII inhibition in heart failure may be substantially mediated by KATP channels. Recognition of CaMKII-dependent downregulation of KATP channel expression as a mechanism for vulnerability to injury in failing hearts points to strategies targeting this interaction for potential preventives or treatments.

Indexed as

Action PotentialsGene Expression RegulationAnimalsCalcium-Calmodulin-Dependent Protein Kinase Type 2Cell MembraneEnzyme ActivationFemaleHeart FailureHeart VentriclesHypertrophyKATP ChannelsMaleMiceMyocardial ContractionMyocardial Reperfusion InjuryProtein Kinase InhibitorsCalcium-Calmodulin-Dependent Protein Kinase Type 2KATP ChannelsProtein Kinase Inhibitors

Identifiers

PMID26964104
PMCPMC4786327
OpenAlexW2296362903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.